medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2009, Number 6

<< Back Next >>

Rev Mex Oftalmol 2009; 83 (6)

Resultados de la quimioterapia inmunosupresora en la queratitis ulcerativa periférica asociada a enfermedades sistémicas inmunes

Hernández-Camarena JC, González-González LA, Rodríguez-García A

Language: Spanish
References: 25
Page: 349-359
PDF size: 115.74 Kb.


ABSTRACT

Purpose: Analyze and provide recommendations on the management of peripheric ulcerative keratitis with systemic immunosuppressors in patients with immune diseases.
Methods: Retrospective non comparative case series of 19 patients (29 eyes) with peripheral ulcerative keratitis managed with immunosuppressive drugs according to the associated immune systemic disease. Therapeutic response, follow-up time, recurrences, ocular complications and adverse effects were analyzed.
Results: The mean age at presentation was 53.05 ± 16.29 years; with an M:F ratio of 1:5.3. The most common associated systemic disease was rheumatoid arthritis (84%). The median follow-up time was 10 months. The mean time of response to immunosuppressive therapy was 8.06 ± 5.63 weeks, with recurrences occurring in 31% of the patients during followup. Ocular complications occurred in 13.7% of the eyes. Adverse effects presented in 36.8% of patients, of these, 85.7% responded to reduction of the immunosuppressive dose.
Conclusions: The use of immunosuppressive therapy in patients with peripheric ulcerative keratitis associated with systemic immune disease provides control of the life- threatening systemic vasculitis and prevents the progression of the inflammatory process. The correct, opportune use of immunosuppresors achieves these objectives in the majority of cases. Failure in implementing an adequate therapy leads to a significant morbid-mortality risk and ocular tissue destruction.


REFERENCES

  1. Ladas JG, Mondino BJ. Systemic disorders associated with peripheral corneal ulceration. Ophthalmol 2000; 11:468-471.

  2. Galor A, Thorne JE. Scleritis and Peripheral Ulcerative Keratitis. Rheum Dis Clin North Am 2007; 33(4):835-854.

  3. Tauber J, Sainz de la Maza M, Hoang-Xuan T y cols. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 1990; Jan 9(1):66-73.

  4. Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis: effects of systemic immunosuppression. Ophthalmol 1984; 1:315-324.

  5. Malik R, Culinane AB, Tole DM, Cook SD. Rheumatoid keratolysis: a series of 40 eyes. Eur J Ophthalmol 2006; 16(6): 791-797.

  6. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 9:1791-1801.

  7. Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30(4):1573-1579.

  8. Jabs DA, Rosenbaum JT, Foster SC. Consensus Panel on Immunosuppression for ocular disease. Am J Ophtalmol 2000; 130(4):492-513.

  9. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL y cols. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford) 2002; 41:1303-1307.

  10. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C y cols. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41:1126-1132.

  11. Rodriguez A. Tratamiento Inmunosupresivo e Inmunomodulador en Pacientes con Enfermedades Inflamatorias Oculares. Avance. 2008; 5(16):26-30.

  12. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular Toxicity of Hydroxychloroquine. Seminars in Ophthalmology 2008, 23:201-209,

  13. McKibbin M, Isaacs JD, Morrell AJ. Incidence of corneal meltng in association with systemic disease in the Yorkshire Region, 1995-1997. Br J Ophthalmol 1999, 83:941-943.

  14. Tauber J, Sainz de la Maza M, Hoang-Xuan T, Foster CS. An analysis of therapeutic decision making regarding immunosuppressive chemotherapy for peripheral ulcerative keratitis. Cornea 1990, 9:66-73.

  15. Gubbels SP, Barkhuizen A, Hwang PH. Head and neck manifestations of Wegener’s granulomatosis. Otolaryngol Clin North Am 2003; 36(4):685-705.

  16. Patel S, Lundy D. Ocular manifestations of autoimmune disease. Am Fam Physician. 2002; 66:991-998.

  17. Erhardt C, Mumford P, Venables P y cols. Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 1989; 48:7-13.

  18. Sainz de la Maza M, Foster S. Ocular Characteristics and Disease Associations in Scleritis-Associated Peripheral Keratopathy. Arch Ophthalmol 2002; 120:15-19.

  19. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993, 11(supp 8):117-119.

  20. Clewes A, Dawson J, Kaye S y cols. Peripheral ulcerative keratitis in rheumatoid arthritis: successful use of intravenous cyclophosphamide and comparison of clinical and serological characteristics. Ann Rheum Dis 2005; 64:961-962.

  21. Messmer E, Foster S. Vaculitic Peripheral Ulcerative Keratitis– Major Review. Surv Ophthalmol 1999; 43(5):379-396.

  22. Atchia I, Kidd E, Bell R. Rheumatoid Arthritis-Associated Necrotizing Scleritis and Peripheral Ulcerative Keratitis Treated Successfully With Infliximab. J Clin Rheumatol 2006; 12: 291-293.

  23. Karamursel E, Thorne J, Qazi FA. Evaluation of Patients with Scleritis for Systemic Disease. Ophthalmology 2004; 111(3): 234:240.

  24. Nguyen QD, Foster CS. Scleral patch graft in the management of necrotizing scleritis. Int Ophthalmol Clin 1999; 39:109-131.

  25. Kubo T, Fujioka M, Ishida M. Clinical condition of steroidinduced osteonecrosis of the femoral head. Clin Calcium 2007; 17(6):856-862.




2020     |     www.medigraphic.com